Jacaranda Biosciences, Inc.
San Francisco, CA Doing business as Jacaranda Biosciences Inc.
- UEI
- MKHLELWDN7D7
- CAGE
- 82GV0
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2908 Baker St, San Francisco, CA 94123, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of UPR-targeted treatment for cisplatin-induced ototoxicity. - abstract: the overall goal of jacaranda… | National Institute on Deafness and Other Communincation Disorders | $304,762 | |
| EIF2B activators to treat noise-induced hearing loss - abstract noise induced hearing loss (nihl) is one of the most… | National Institute on Deafness and Other Communincation Disorders | $4,545,303 | |
| EIF2B activators to treat noise-induced hearing loss - abstract the overall goal of jacaranda biosciences, INC. (JBI) is… | National Institute on Deafness and Other Communincation Disorders | $599,998 |
About Jacaranda Biosciences, Inc.
Jacaranda Biosciences, Inc. is a biotechnology company located in San Francisco, California, focusing on developing innovative therapeutic compounds for hearing loss prevention and treatment. Registered in SAM.gov since March 2018, the company operates as a for-profit corporate entity with a specific research focus on addressing hearing-related medical challenges. The organization has been actively pursuing federal grant funding from the National Institute on Deafness and Other Communication Disorders (NIDCD) to advance its research and development efforts in novel therapeutic interventions.
The company has secured multiple Small Business Innovation Research (SBIR) grants targeting specific hearing loss mechanisms, particularly through research on the unfolded protein response (UPR) pathway. Their federal grant awards, totaling approximately $304,762 for a Phase 1 project and additional funding for Phase 2 development, concentrate on developing compounds to prevent ototoxicity and hearing loss caused by cisplatin chemotherapy and noise-induced hearing damage. Specifically, Jacaranda Biosciences has been developing EIF2B activator compounds designed to protect cochlear hair cells from death and mitigate hearing loss in various contexts, including chemotherapy-induced hearing damage and noise-induced hearing loss. The research aims to create therapeutic interventions for a patient population of over 40 million Americans affected by hearing loss, with the ultimate goal of preparing compounds for potential investigational new drug (IND) applications and future clinical trials.
Quick answers
What is Jacaranda Biosciences, Inc.'s UEI?
Jacaranda Biosciences, Inc.'s Unique Entity ID (UEI) in SAM.gov is MKHLELWDN7D7.
What is Jacaranda Biosciences, Inc.'s CAGE code?
Jacaranda Biosciences, Inc.'s CAGE code is 82GV0.
Where is Jacaranda Biosciences, Inc. located?
Jacaranda Biosciences, Inc.'s physical address in SAM.gov is 2908 Baker St, San Francisco, CA 94123, USA.
Is Jacaranda Biosciences, Inc. registered in SAM.gov?
Yes. Jacaranda Biosciences, Inc.'s SAM.gov registration is active through June 16, 2027.
What is Jacaranda Biosciences, Inc.'s most recent federal award?
Jacaranda Biosciences, Inc.'s most recent federal grant award is Development of UPR-targeted treatment for cisplatin-induced ototoxicity. - abstract: the overall goal of jacaranda… (R43DC021398), from National Institute on Deafness and Other Communincation Disorders, on July 2, 2024.
On GovTribe
See Jacaranda Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors